Cleanup for the IL-23 class in ulcerative colitis as new drugs ‘rapidly gained significant momentum’: report November 18, 2024
Hope on the Horizon: Nephrologists Emphasize Need for Innovative C3G Treatments as Novartis and Apellis Prepare Therapies for FDA Submission November 15, 2024
Tremfya’s Promising Debut Boosts Momentum for IL-23 Class in Ulcerative Colitis Treatment, According to Spherix Global Insights November 15, 2024
Humira, Cosentyx gaining favor as treatments for hidradenitis suppurativa, but more support for biologics needed: Spherix November 12, 2024
